Aldeyra Therapeutics, Inc. Sustainability Profile
Aldeyra Therapeutics, Inc., a pioneering biotechnology company based in the United States, focuses on developing innovative therapies for immune-mediated diseases. Founded in 2011, Aldeyra has made significant strides in the field of ocular and systemic diseases, particularly through its unique approach to harnessing the power of the immune system. The company’s flagship products, including reproxalap, target unmet medical needs in conditions such as dry eye disease and allergic conjunctivitis, setting them apart with their novel mechanisms of action. Aldeyra's commitment to advancing therapeutic options has positioned it as a notable player in the biotechnology industry, with a growing portfolio of clinical-stage assets and a strong emphasis on research and development.
DitchCarbon Score
How does Aldeyra Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aldeyra Therapeutics, Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aldeyra Therapeutics, Inc.'s reported carbon emissions
Aldeyra Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Consequently, there are no documented Scope 1, 2, or 3 emissions or any reduction targets or achievements available for review. The company has not established any formal climate commitments or initiatives, such as Science-Based Targets (SBTi) or other reduction pledges. As a result, Aldeyra Therapeutics, Inc. does not have a publicly available framework for addressing carbon emissions or climate impact at this time. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and emissions reduction. However, without specific data or commitments from Aldeyra Therapeutics, it remains unclear how they align with these industry trends.
How Carbon Intensive is Aldeyra Therapeutics, Inc.'s Industry?
How Carbon Intensive is Aldeyra Therapeutics, Inc.'s Location?
Aldeyra Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aldeyra Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
